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Cell cycleA short G1 phase is a characteristic feature of the cell cycle structure of pluripotent cells, and is rees-
tablished during Yamanaka factor-mediated pluripotent reprogramming. How cell cycle control is
adjusted to meet the requirements of pluripotent cell fate commitment during reprogramming is
less well understood. Elevated levels of cyclin D1 were initially found to impair pluripotency main-
tenance. The current work further identiﬁed Cyclin D1 to be capable of transcriptionally upregulat-
ing Pax6, which promoted reprogramming cells to commit to a neural progenitor fate rather than a
pluripotent cell fate. These ﬁndings explain the importance of reestablishment of G1-phase restric-
tion in pluripotent reprogramming.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Pluripotent cells in the inner cell mass exhibit a shortened G1
phase and lack G1 checkpoint regulation [1,2], while neural
stem/progenitor cells (NPCs) have a tightly regulated and length-
ened G1 phase associated with their self-renewal and differentia-
tion status [3–5]. For example, Lange et al., have recently shown
that G1 lengthening is critically regulated during the expansion
and differentiation of NPCs into neurons, and Artegiani et al., dem-
onstrated that overexpression of cell cycle regulators cdk4 or cyclin
D1 can trigger the expansion of NPCs in adult mouse brain [4,6].
Others have shown that cyclin A2 critically regulates the cell cycle
of pluripotent embryonic stem (ES) cells [2,7–9], and a shortened
G1 phase protects ES cells from external signals that can induceendodermal or neuroectodermal differentiation [10]. These ﬁnd-
ings suggest that cell cycle state is modulated during the differen-
tiation process in order to meet the requirements of cell fate
commitment during development. However, the key regulators
that link cell cycle remodeling and cell fate commitment remain
to be explored.
Pluripotent reprogramming, achieved by introducing Yamanaka
factors (Oct4, Sox2, c-Myc and Klf4) into somatic cells, has been
used to study the pathogenesis of inherited genetic diseases and
to identify novel drug targets [11–13]. Recent studies have further
demonstrated that Yamanaka factor-mediated ﬁbroblast repro-
gramming can generate not only induced pluripotent stem (iPS)
cells, but also cells that possess features of multipotent hematopoi-
etic progenitors [14] or NPCs [15,16]. Previous work by Ruiz et al.,
has already shown that cell cycle features of ES cells are acquired
during pluripotent reprogramming induced by Yamanaka factors
[17]. These ﬁndings imply that the fate of cells undergoing repro-
gramming may be tightly associated with cell cycle remodeling.
The present study investigated whether regulators involved in
reestablishment of cell cycle structures of ES cells or NPCs during
Yamanaka factor-mediated reprogramming are also cell fate
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G1 phase regulator, during reprogramming possibly acts as a bar-
rier to the successful generation of iPS cells by promoting neural
progenitor fate commitment through transcriptionally upregulat-
ing Pax6.
2. Materials and methods
2.1. Generation of Oct4-EGFP-positive iPS cells
Oct4-EGFP-positive iPS cells were generated as previously
described [11,12]. Brieﬂy, for retrovirus packaging and production,
pMXs retroviral vectors encoding Oct4, Sox2, Klf4, and c-Myc
(obtained from Addgene) were transfected into plat-E cells using
polyJet transfection reagents (SignaGen). Passage 1 tail-tip ﬁbro-
blasts (TTFs) were seeded on 6-well plates at a density of 1  105
cells/well for 24 h before retroviral infection. The retrovirus
supernatants containing Oct4, Sox2, Klf4, and c-Myc were added
equally to 6-well plates and incubated for 24 h with 4 lg/ml polyb-
rene. The next day, the virus-containing mediumwas removed and
replaced with ﬁbroblast medium. On day 4, 5  104 virus-infected
TTFs were seeded on mitomycin C-treated mouse embryonic ﬁbro-
blast (MEF) feeders and incubated in ES-cell culture medium with
leukemia inhibitory factor (LIF) until reprogramming was com-
plete. After 4 passages, the homogenous EGFP+ colonies were
picked and evaluated for pluripotency.
2.2. RNA-Seq analysis
RNA was isolated using TRIzol (Invitrogen) according to the
manufacturer’s instructions. Seven to ten million single-end RNA-
Seq reads, of 101 basepairs in length, were generated using an Illu-
mina sequencer and analyzed with CLC Genomics Workbench 4.9
(http://www.clcbio.com). Initially, the reads were trimmed accord-
ing to quality score and base ambiguity. The processed reads were
then mapped to the mouse RefSeq genomic sequences with anno-
tations. The mapped reads of each gene were taken into account to
calculate Reads per Kilobase of exon model per Million mapped
reads (RPKM), a gene expression measure for RNA-Seq data. For
non-speciﬁc matches, gene expression was ﬁrst estimated based
on the reads uniquely mapped to the gene, and then used as a
weight for the distribution of non-speciﬁcally mapped reads. Con-
sequently, 14480 of 34240 predicted genes had at least one
mapped read and were detected in more than 3 of 6 samples. R-
project was employed to perform the hierarchical clustering of
these genes.
Additional methods are described in the Supplementary
material.3. Results and discussion
3.1. Cyclin D1 is induced during cell reprogramming and is co-
expressed with neural progenitor markers but not with pluripotency
markers
To identify the factors controlling the commitment of repro-
gramming cells to a pluripotent cell fate, TTFs isolated from 4-
week-old mice carrying an Oct4-DPE-enhanced green ﬂuorescent
protein (Oct4-EGFP) reporter [18] were transduced with retrovi-
ruses carrying Oct4, Sox2, c-Myc and Klf4. The cells were then cul-
tured on MEF feeders in ES-cell culture medium with LIF. After
transduction for 19 days, cell clusters exhibiting a morphology
similar to that of ES cells appeared in culture (Fig. 1A). However,
very few cell clusters were found to express EGFP. Immunoﬂuores-
cent staining revealed that the majority of EGFP cell clusters werepositive for Nestin (Fig. 1B), while EGFP+ cells expressed Nanog
(Fig. 1C). To further examine why EGFP cells were not repro-
grammed into pluripotent cells, the reprogramming cells were
divided based on surface expression of EGFP and Stage-Speciﬁc
Embryonic Antigen-1 (SSEA1) [19]. We distinguished three sub-
populations using a FACSAria cell sorter: EGFP+/SSEA1+ (G+/S+),
EGFP/SSEA1+ (G/S+), and EGFP/SSEA1 (G/S) (Supplementary
Fig. 1A). The G+/S+ cell subpopulation was found to display high
alkaline phosphatase (AP) activity and features of pluripotent stem
cells, including expression of Nanog, SSEA1 and E-cadherin (Sup-
plementary Fig. 1B–E). In contrast, the EGFP cell subpopulations
(G/S+ and G/S) did not express EGFP or Nanog, although low
levels of AP activity were present. RNA-seq analysis was performed
on these three subpopulations together with TTFs, mouse TT2-ES
cells, and mouse iPS cells (derived from 30 passages of G+/S+ cells
in continuous culture). Hierarchical clustering analysis and RT-
PCR analysis conﬁrmed that a panel of pluripotency genes includ-
ing Nanog and Gdf3 were up-regulated in the G+/S+ cell population
(Fig. 1D and E, Supplementary Fig. 2A and B). Both G/S+ and G/S
cell subpopulations expressed higher levels of Ccnd1 (cyclinD1)
together with some neural genes including Pax6 and Nestin. Inge-
nuity Pathway Analysis (IPA) revealed that these neural genes
are involved either in regulating the self-renewal of NPCs or in
development of the central nervous system (Fig. 1D and E, Supple-
mentary Fig. 2A–C). Immunoﬂuorescent staining further conﬁrmed
that the majority of cyclin D1hi/EGFP cell clusters was positive for
Nestin and Sox1 (Fig. 1F and G). These results suggest that repro-
gramming cells in the G+/S+ subpopulation were becoming plurip-
otent cells, while a large proportion of cyclin D1hi cells in the G/S+
and G/S subpopulations were committed to neural progenitor
fates.
3.2. Subpopulations of reprogramming cells exhibit distinct cell cycle
structure
To explore the regulators that link cell cycle remodeling and cell
fate commitment during Yamanaka factor-mediated ﬁbroblast
reprogramming, the expression patterns of cell-cycle regulators
were examined in the different reprogramming cell populations
after transduction with Yamanaka factors for 17 days. Immunoﬂu-
orescent staining showed that EGFP cell clusters that expressed
Pax6 also displayed higher levels of Cdk6. In contrast, EGFP+ cell
clusters that were positive for Nanog expressed low levels of
Cdk6 (Fig. 2A and B, arrowed cells). Western blot analysis further
conﬁrmed that cyclins A, B1, and H, as well as Cdk1 and Cdk7, were
highly expressed in EGFP+ cell subpopulations and in ES cells, while
EGFP cell subpopulations expressed high levels of cyclin D1, D2,
and D3, and Cdk6 (Fig. 2C). We then investigated the percentage
of cells in each phase of the cell-cycle using DAPI staining together
with 5-ethynyl-20-deoxyuridine (EdU) labeling (Fig. 2D). In con-
trast to TTFs, which have the majority of cells in G0/G1 phase,
G+/S+ cells possessed cell-cycle characteristics similar to those of
ES cells, with the majority of cells in S phase. The majority of G/
S and G/S+ cells were in G0/G1 phase.
KEGGmapping applied to the data obtained from RNA-seq anal-
ysis conﬁrmed differences in the expression patterns of cell-cycle
regulators among TTFs, G/S, G/S+,G+/S+, iPS and ES cells (Supple-
mentary Fig. 3A). G+/S+ cells expressed higher levels of S and G2/M
phase regulators including Ccne1, Ccna2 and Ccnb1 (which are
known to promote entry into S and G2/M phases, Supplementary
Fig. 3C and D), while EGFP cell subpopulations (G/S and G/
S+) expressed higher levels of G1 phase regulators including Ccnd1,
Cdk6, Cdkn1a, and Cdkn1b (which are known to form kinase com-
plexes regulating entry into G1 phase, Supplementary Fig. 3B). Fur-
ther characterization showed that the majority of cyclin D1hi/
EGFP cells were associated with expression of a panel of neural
Fig. 1. Cyclin D1 is induced during cell reprogramming and is co-expressed with neural progenitor markers but not with pluripotency markers. TTFs isolated from 4-week-old
mice carrying an Oct4-EGFP reporter were transduced with retroviruses carrying Oct4, Sox2, c-Myc and Klf4. (A–C) The reprogramming cells at day 19 were ﬁxed and stained
with anti-Nanog (purple) and anti-Nestin (red) antibodies. Cell nuclei were counterstained with Hoechst dye (blue) and EGFP is in green. Only the EGFP-positive cells also
express Nanog. Scale bar represents 50 lm. (D and E) The reprogramming cells were divided into three subpopulations: G+/S+, G/S+, and G/S based on surface expression of
EGFP (G) and SSEA1 (S) analyzed using a FACSAria cell sorter. (D) Hierarchical clustering analysis of gene expression patterns of TTF (passage 2), G/S (passage 5), G/S+
(passage 5), G+/S+ (passage 5), G+/S+ (passage 30), and ES cells. The Reads per Kilobase of exon per Million mapped reads (RPKM) of RNA sequences determined as described in
the Section 2 were taken log2 and the hierarchical clusters were determined using the hclust method of R-project. Only genes with more than a twofold difference between
any pair of samples from different classes are shown in the heat map. The pluripotent, neural stem/progenitor, and cell cycle regulators were isolated for hierarchical
clustering analysis. (E) Total RNA was extracted from TTF (passage 2), G/S (passage 5), G/S+ (passage 5), G+/S+ (passage 5), and ES cells. The selected genes in control and
experimental groups were analyzed by RT-PCR with speciﬁc primers. For reprogramming genes, ‘‘endo’’ refers to PCR with primers speciﬁc for the endogenous gene, and
‘‘total’’ to PCR with primers detecting expression of both the endogenous and retrovirally encoded genes. (F and G) The reprogramming cells at day 17 were ﬁxed and stained
with anti-Nestin (red), anti-Sox1 (red) and anti-cyclin D1 (purple) antibodies. EGFP is in green. Cell nuclei were counterstained with Hoechst dye (blue). Scale bar represents
50 lm.
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Fig. 4) and high levels of cyclin D1 were correlated with expression
of Pax6 (Supplementary Fig. 5A and B). In contrast, cyclin D1 levels
were negatively correlated with Nanog and Oct4-EGFP expression
(Supplementary Fig. 5C–F).Noticeably, we found that EGFP cells grew slower and had
longer doubling time (18 h) than did EGFP+ cells (12 h). To further
determine if the higher proportion of EGFP cell in G0/G1 phase
was due to increases in length of G1 phase in comparison to EGFP+
cells, EGFP+ and EGFP cells were synchronized in mitotic phase by
Fig. 2. Subpopulations of reprogramming cells exhibit distinct cell cycle properties. (A and B) Day 17 reprogramming cells were ﬁxed and stained with anti-Pax6 (red), anti-
Nanog (red), and anti-CDK6 (green) antibodies. Cell nuclei were counterstained with Hoechst dye (blue). Scale bar represents 50 lm. (C) Total proteins were isolated from
TTFs (passage 3), G/S (passage 5–6), G/S+ (passage 5–6), G+/S+ (passage 5–6), and ES cells for Western blot analysis, and 20 lg total protein were loaded for antibody
detection; a-tubulin was used as an internal control. (D) Subpopulations of reprogramming cells were labeled with EdU (10 lM for 45 min) and ﬁxed. Incorporation of EdU
was detected with azide-conjugated Alexa649 and cells were incubated with DAPI for chromosome staining. The cells were analyzed with FACSCanto. (E–G) Synchronization
of Oct4-EGFP+ and Oct4-EGFP cells with colcemid (40 ng/ml for 7 h) followed by their release from the mitotic arrest. The cells were labeled with EdU after removing the
colcemid and were isolated at different time points and ﬁxed with 4% PFA. The percentages of G0/G1, S, and G2/M phase of the cell cycle were analyzed by FACSCanto
cytometry based on EdU and DAPI signal intensity.
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after their release from the mitotic arrest, both EGFP+ and EGFP
cells had undergone transition from M-to-G1 phase (Fig. 2F and
G). EGFP+ cells were found to have a rapid transition from G1-to-
S phase, between 2 and 4 h, in comparison to EGFP cells where
the G1-to-S phase transition occurred after 5 h (Fig. 2F and G).
Taken together, these ﬁndings indicate that, in comparison to
EGFP+ cells, cyclin D1hi/EGFP cells exhibit a lengthened G1 phase
and display NPC-like characteristics.
3.3. Elevated levels of cyclin D1 impair pluripotency maintenance and
promote neural differentiation
EGFP+ cells possessed several pluripotency features including (i)
absence of CpG methylation in the Nanog promoter region
(Fig. 3A), (ii) were positive for Nanog expression (Fig. 3B), and
(iii) had the capability to differentiate into cells of the three germ
layers in vivo and in vitro (Fig. 3C–E). Pluripotent ES cells exhibit
an unusual cell-cycle that has a lengthened S phase and a very
short G1 phase [7,21,22]. We reasoned that evaluated level of
cyclin D1 may affect pluripotency maintenance. We therefore next
examined if overexpression of Cyclin D1 affects pluripotency char-
acteristics of EGFP+ cells. To address this question, cyclin D1 was
overexpressed (Fig. 3F–H) in G+/S+ cells at passage 1 and FACS-
puriﬁed cells were continuously passaged 4 times on MEF feeders
in LIF-containing medium before being analyzed by immunoﬂuo-
rescent staining and ﬂow cytometry. As shown in Fig. 3F and G,
overexpression of cyclin D1 led to a 72% reduction in the number
of EGFP+ cells. RT-PCR analysis further conﬁrmed that the reduc-
tion in EGFP+ cells was accompanied by decreased expression of
a panel of pluripotency genes that included Oct4, Sox2, c-Myc,
Klf4, Cripto, Gdf3, n-Myc, Nanog, SOCS3 and Dppa3 (Fig. 3H). We
addressed the issue further by overexpressing cyclin D1 in iPS cells
(Fig. 3I and J) and in ES cells (Fig. 3K–N), and observed the appear-
ance of Nestin-expressing colonies composed of cells displaying an
elongated cell morphology (Fig. 3N) accompanied by loss of EGFP
(Fig. 3J, arrowed cells) or Nanog expression (Fig. 3M, arrowed
cells). EB formation and teratoma formation experiments showed
that overexpression of cyclin D1 promoted the differentiation of
iPS and ES cells into neural lineages (Supplementary Fig. 6A–C,
G–J and M–O).
3.4. Cyclin D1 regulates neural progenitor fate commitment during
Yamanaka factor-mediated ﬁbroblast reprogramming
To further investigate how cyclin D1hi/EGFP cells become com-
mitted to an NPC-like cell fate during reprogramming, day 9 EGFP
cells were collected and seeded on poly-L-lysin/laminin-coated
glass coverslips in NPC growth medium. The cells were found to
express cyclin D1 and NPC markers including Sox1, Nestin, Pax6
and CD133 (Fig. 4A–C. Supplementary Fig. 7A–D), and were able
to form neurospheres and to be continuously passaged more than
10 times without losing their growth capacity (Supplementary
Fig. 7E). Replacing the NPC growth mediumwith serum-containing
medium could trigger sphere cells to differentiate into Tuj1+ neu-
rons, GFAP+ glial cells and O4+ oligodendrocyte precursor cells
(Fig. 4D–F). Since RT-PCR and FACS analysis (Supplementary
Fig. 4D–G) showed that cyclin D1 was up-regulated by transduc-
tion with Yamanaka factors and was associated with increased
expression of NPC genes, we investigated whether cyclin D1 is
involved in regulating the generation of NPC-like cells during
reprogramming. TTFs were transduced with Yamanaka factors
and subjected to shRNA-mediated Ccnd1 knockdown (70% knock-
down efﬁciency, Supplementary Fig. 8A and D). After 14 days in
culture, a signiﬁcant reduction in the number of total colonies
(reduced by 39%) and of Pax6-positive cell clusters (reduced by39%) was observed, and was accompanied by a reduced prolifera-
tion rate and decreased expression of Sox3, Pax6 and Gfap
(Fig. 4G–I; Supplementary Fig. 8A–E). Additionally, an increased
proportion of reprogramming cells was observed to differentiate
into Tuj1+ (b3-tubulin-expressing) neuronal cells (Supplementary
Fig. 8B and E). Indeed, Cyclin D1 is known to be involved in regu-
lating the self-renewal expansion of NPCs [4], and reduction of
cyclin D1 can promote differentiation of NPCs to neuron. The
results suggest that Ccnd1 knockdown possibly affects mainte-
nance of reprogramming cell-derived NPCs and progenitor cell fate.
Importantly, cyclin D1 was found to negatively modulate the
generation of iPS cell precursors at an early reprogramming stage,
as Nanog-expressing colonies were found to increase by 220%
(Fig. 4J). RT-PCR analysis further conﬁrmed that the increase in
Nanog-expressing cells was accompanied by up-regulation of a
panel of pluripotent genes including Cripto, Gdf3, n-Myc, Dppa3
and Nanog (Fig. 4K). Cyclin D1 was further knocked down in G+/
S+ cells at passage 1, and FACS-puriﬁed cells were continuously
passaged 4 times on MEF feeders in LIF-containing medium before
being analyzed by immunoﬂuorescent staining and ﬂow cytome-
try. As shown in Fig. 4L, cyclin D knockdown led to a 124% increase
in the number of EGFP+ cells. The shRNA-mediated Ccnd1 knock-
down was further carried out in iPS and R1-ES cells. This did not
affect the expression of pluripotency markers (data not shown),
but in vitro differentiation experiments showed that Ccnd1 knock-
down reduced the capability of ES and iPS cells to differentiate into
neural lineages (Supplementary Fig. 6D–F, K and L). The ﬁndings
suggest that a reduction in cyclin D1 would be beneﬁcial for pluri-
potency maintenance.
3.5. Cyclin D1 promotes neural progenitor fate commitment and
suppresses pluripotent reprogramming via transcriptionally
modulating expression levels of Pax6 and Nanog
To further explore how elevated levels of cyclin D1 can promote
the commitment of reprogramming cells to a neural progenitor
fate, we analyzed the binding sites of transcriptional factors in
the Pax6 promoter region using PROMO 3.0 [23], and found that
the Yamanaka factors Oct4, Sox2, Klf4, and c-Myc can potentially
bind to a 2 kb region of the Pax6 promoter. To examine whether
cyclin D1 transcriptionally regulates Pax6 expression, we prepared
a luciferase reporter construct containing 2 kb of the Pax6 pro-
moter region (Fig. 5A). Moreover, using a genetic-proteomic
screen, Bienvenu et al., previously demonstrated that cyclin D1
affects transcription during development [24]. According to data
obtained from chromatin immunoprecipitation experiments,
cyclin D1 can bind via interaction with NF-Y to the 100 to
200 bp region of the Pax6 promoter in retinal cells. Using a co-
immunoprecipitation assay, we initially validated that cyclin D1
can form a complex with NF-Y in reprogramming cells (Fig. 5B).
We then further showed that overexpression of cyclin D1 or cyclin
D1 T286A mutant (less degradable form) [25] increased Pax6 pro-
moter activity (Fig. 5C). In contrast, constitutive expression of
kinase-dead mutant, cyclin D1-K112E, suppressed Pax6 promoter
activity (Fig. 5C) [26]. The results imply that cyclin D1 is able to
transcriptionally regulate Pax6 expression in reprogramming cells.
Pax6 is a transcriptional determinant of the neuroectodermal
fate during development [27]. In order to evaluate whether expres-
sion of Pax6 critically regulates the commitment of reprogram-
ming cells to NPCs, TTFs were transduced with Yamanaka factors
with or without overexpression of Pax6. After transduction for
17 days, expression of Nanog and Nestin was examined using
immunoﬂuorescent staining. The majority of reprogramming cells
expressed Nestin (Fig. 5D–F). The number of EGFP+ and Nanog+ col-
onies was reduced by 93% and 90% (Fig. 5G and H), respectively,
accompanied by down-regulation of a panel of pluripotent genes
Fig. 3. Constitutive expression of Ccnd1 in Oct4-EGFP+ cells impairs pluripotency maintenance. (A) Genomic DNA isolated from TTF, G/S (passage 5), G/S+ (passage 5), G+/
S+ (passage 5), and mES cells was used for bisulﬁte sequencing. Black ovals indicate the presence and white ovals the absence of methyl-CpG at positions in the region
analyzed. (B) G+/S+ cells at passage 5 were ﬁxed and stained with anti-Nanog (red) antibodies. Cell nuclei were counterstained with Hoechst dye (blue). (C) 1  106 G+/S+ cells
were subcutaneously injected into NOD/SCID mice, which were analyzed for formation of teratomas after 1 month. (D) 1  106 G+/S+ cells were plated on 6 cm petri dishes
with 5 ml mES culture medium without LIF. The G+/S+ cells and embryoid bodies were collected at days 0, 3, and 5. RT-PCR analysis was performed to determine the
expression of pluripotency markers Klf4 and Rex1, ectodermal marker Sox1, mesodermal marker Brachyury(T), and endodermal marker Sox17. (E) 3-Day embryoid bodies were
seeded on culture dishes in culture medium without LIF and were grown for 5 days. Attached cells were then ﬁxed and stained with anti-AFP (hepatocytes, endoderm), anti-
cTnT (cardiomyocytes, mesoderm) and Tuj1 (neurons, ectoderm) antibodies. Cell nuclei were counterstained with Hoechst dye (blue). (F–H) Day 17 reprogramming cells
were transfected with pLKO.1-EF1-IRES-mCherry (vector control) or pLKO.1-EF1-cyclin D1-IRES-mCherry. After 48 h, cells that were EGFP+ and mCherry+ were puriﬁed using
a FACSAria cell sorter and then cultured on MEF feeders. The reprogramming cells at passage 4 were ﬁxed and stained with anti-cyclin D1 (purple) antibodies (cell nuclei were
counterstained with Hoechst dye (blue) and EGFP is in green (F). The reprogramming cells at passage 4 were analyzed by a FACSAria cell sorter (G) or analyzed by real-time
quantitative PCR (H) for Oct4, Sox2, c-Myc, Klf4, Cripto, Gdf3, n-Myc, Nanog, SOCS3, Dppa3, and Tbx3. Values shown are mean ± S.E.M., n = 3. ⁄p < 0.05, ⁄⁄p < 0.01, ⁄⁄⁄p < 0.001
indicates that the difference between mCherry and Ccnd1 treatment was statistically signiﬁcant. Mann–Whitney test was used for determining statistical signiﬁcance. (I and
J) Photos of cell morphologies of control (mCherry vector only) or Cyclin D1-overexpressing iPS cells were taken under bright ﬁeld or GFP channel. Arrows mark the
differentiated cells with weak GFP and neural cell morphology. (K and M) Immunoﬂuorescent staining was performed for cyclin D1 (purple), and Nanog (green) onmCherry or
Ccnd1 transgenic ES-R1. The panels labeled ‘‘merge image’’ show these stainings merged with anti-Nanog in green, anti-cyclin D1 in purple, and staining of cell nuclei with
Hoechst dye in blue. Arrowheads mark the differentiated cells with weak Nanog. Scale bar represents 50 lm. (L and N) Immunoﬂuorescent staining of cyclin D1 (purple) and
Nestin (green) on mCherry or Ccnd1 transgenic ES-R1. The merge image represents an overlay of the anti-Nestin, and anti-cyclin D1 images along with the Hoechst33342
stained images for DNA. Scale bar represents 50 lm.
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Fig. 4. Cyclin D1 modulates neural progenitor commitment in cell reprogramming, (A–F) Characterization of sphere-forming cells derived from Yamanaka factor-mediated
TTF reprogramming. Cyclin D1 expression was found to be highly correlated with Sox1 and Pax6 expression in EGFP cells. (A) Day 9 EGFP reprogramming cells were grown
in neurosphere culture medium for several passages. The sphere cells at passage 8 were ﬁxed and stained with anti-cyclin D1 (green) and anti-Sox1 (red) antibodies. Cell
nuclei were counterstained with Hoechst dye (blue). (B and C) The EGFP spheres were resuspended as single cells, seeded on poly-L-lysin/laminin coated coverslips, and
cultured until 70–80% conﬂuent. Cells were then ﬁxed and stained with anti-Sox1 (red)/anti-Nestin (green) or anti-Pax6 (red)/anti-Nestin (green) antibodies. Cell nuclei were
counterstained with Hoechst dye (blue). (D–F) The sphere cells at passage 8 were seeded in either growth factor-withdrawn medium (for neuronal differentiation) or serum-
containing medium (for glial and oligodendrocyte differentiation) for 5 days, and then were ﬁxed and stained with anti-Tuj1 (red), anti-GFAP (red) or anti-O4 (green)
antibodies. Cell nuclei were counterstained with Hoechst dye (blue). (G–K) Day 3 reprogramming cells were infected with lentivirus carrying shCcnd1 or shScramble and
selected with puromycin from day 5 to day 17. Day 17 reprogramming cells were ﬁxed and stained with anti-Pax6 (red) or anti-Nanog antibodies. Cell nuclei were
counterstained with Hoechst dye (blue). Total colonies, Pax6+, and Nanog+ colonies derived from reprogramming cells infected with lentivirus carrying shCcnd1 or shScramble
were counted under a microscope. Gene expression was analyzed by real-time quantitative PCR (K) for Ccnd1, Cripto, Gdf3, n-Myc, Nanog, and Dppa3. Values shown are
mean ± S.E.M., n = 3. ⁄⁄p < 0.01, ⁄⁄⁄p < 0.001 indicate that the differences between shScramble and shCcnd1 treatments were statistically signiﬁcant. Mann–Whitney test was
used for determining statistical signiﬁcance. Scale bar represents 50 lm. (L) G+/S+ cells at passage 1 were infected with lentivirus carrying shCcnd1 or shScramble and were
selected with puromycin for another 3 days. The reprogramming cells at passage 4 were analyzed by a FACSAria cell sorter. Values shown are mean ± S.E.M., n = 3. ⁄p < 0.05
indicates that the difference between shScramble and shCcnd1 treatment was statistically signiﬁcant. Mann–Whitney test was used for determining statistical signiﬁcance.
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et al. showed that overexpression of Pax6a is sufﬁcient to trigger
human ES cells to differentiate into neuroectodermal lineages via
induction of neural genes [27]. The report further demonstrated
that Pax6a or Pax6b could repress pluripotency through direct
binding to pluripotency gene promoters. The current ﬁndingsimply a similar regulatory mechanism may be present in mouse
pluripotent cells.
The observation that Nanog expression levels were altered after
cyclin D1 overexpression or knockdown in G+/S+, iPS and ES cells
(Figs. 3H and M and 4K) led us to question whether, in addition
to repression of pluripotency by direct binding of Pax6 to pluripo-
Fig. 5. Cyclin D1 promotes cell reprogramming to neural progenitor commitment by transcriptionally regulating Pax6. (A) Schematic diagram of the 2 kb Pax6 promoter
region. Potential transcription factor binding sites were analyzed with Promo 3.0 software [23]. (B) Total cell extracts (1.5 mg) from EGFP cells at passage 5 were
immunoprecipitated (IP) with anti-cyclin D1 antibody (2 lg) (lane 4) or a mouse IgG (2 lg) (lane 3). The immunoprecipitates were separated by SDS–polyacrylamide gel
electrophoresis, transferred to a PVDF membrane, and probed with anti-cyclin D1 antibody or anti-NF-YA antibody. Cell lysates (20 lg) were also immunoblotted as an input
control (lane 1). (C) Sphere cells derived from EGFP reprogramming cells at passage 10 were used for the Pax6 reporter assay. ⁄p < 0.05, ⁄⁄p < 0.01, ⁄⁄⁄p < 0.001, indicate that
the differences between mCherry, Ccnd1, Ccnd1 K112E, and Ccnd1 T286A treatments were statistically signiﬁcant. Kruskal–Wallis test was used for determining statistical
signiﬁcance. (D–I) TTF cells were transduced with retroviruses carrying Oct4/Sox2/Klf4/c-Myc (OSKM) or Oct4/Sox2/Klf4/c-Myc/Pax6 (OSKMP) and passaged to inactivated MEF
feeders in ES culture medium with LIF. After 17 days the reprogramming cells were ﬁxed with 4% PFA and stained with anti-Nestin (yellow) and anti-Nanog (red) antibody (D
and E). Cell nuclei were counterstained with Hoechst dye (blue). Scale bar represents 50 lm. (F) Pax6 expression level was quantiﬁed with real time qPCR. (G and H) Oct4-
EGFP+ or Nanog+ colonies derived from Oct4/Sox2/Klf4/c-Myc (OSKM) or Oct4/Sox2/Klf4/c-Myc/Pax6 (OSKMP) were counted under a microscope. (I) The relative gene
expression levels of reprogramming cells at Day 17 were analyzed by real-time quantitative PCR for Ccnd1, Cripto, Gdf3, n-Myc, Dppa3, and Nanog. Values shown are
mean ± S.E.M., n = 3. ⁄⁄⁄p < 0.001 and ⁄⁄p < 0.01, indicate that the differences between OSKM and OSKMP treatments were statistically signiﬁcant. Mann–Whitney test was
used for determining statistical signiﬁcance. (J) The 2.5 kb Nanog promoter region was analyzed using Promo 3.0 software; the schematic diagram shows potential cyclin D1/
NF-Y binding sites. (K–M) For the Nanog reporter assay, the plasmids were transfected with Lipofectamine 3000 and refreshed with ES culture medium after 24-h incubation.
At 48 h of transfection, the cells were lysed and the suspension was used in a luciferase activity assay. (K and L) The Nanog promoter activity assay in NIH-3T3 cells was
performed in the condition of Ccnd1 knockdown or treatment with the CDK4/6 inhibitor PD0332991. (M) The Nanog promoter activity assay in NIH 3T3 cells was performed
with overexpression of Ccnd1 T286A mutant. The value shown is mean ± S.E.M., n = 3. ⁄p < 0.05, ⁄⁄⁄p < 0.001, indicates that the difference between control and experimental
groups was statistically signiﬁcant. Mann–Whitney test was used for determining statistical signiﬁcance. (N) Proposed model explains how cyclin D1 acts as a barrier to
pluripotent reprogramming by promoting neural progenitor fate commitment. During reprogramming, cyclin D1 can be induced by Yamanaka factors at the initial phase.
Sustained production of cyclin D1 can trigger Pax6 expression, which leads to the commitment of reprogramming cells to a neural progenitor fate. In contrast, if cyclin D1
levels are reduced in reprogramming cells, an ES cell-like cell cycle structure can therefore be reestablished, leading to completely pluripotent reprogramming.
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the level of pluripotency genes. To address this, we analyzed the
binding sites of transcriptional factors in the Nanog promoter using
PROMO 3.0 [23] and found that cyclin D1 can potentially bind, via
interacting with NF-Y, to at least 5 sites within the 2.5 kb region of
the Nanog promoter. A luciferase reporter assay utilizing a Nanog5P
reporter [28] revealed that Ccnd1-knockdown or treatment with
the Cdk4/6 inhibitor PD0332991 increased Nanog5P reporter
activity (Fig. 5J–L). In contrast, overexpression of the stable cyclin
D1-T286A mutant suppressed Nanog promoter activity (Fig. 5M)
[28]. These results suggest that cyclin D1 may act as a transcrip-
tional suppressor of Nanog.
The current work demonstrates that cell cycle control is
adjusted upon transduction with Yamanaka factors in order to
meet the requirements of cell fate commitment either to pluripo-
tent or neural progenitor fate during reprogramming. In addition
to the well-established role of cyclin D1 as a G1 phase regulator,
our work now suggests a transcriptional role for cyclin D1 in
Pax6 expression, which promotes reprogramming cells towards a
neural progenitor fate. We further revealed a requirement for
CDK4/6 activity in cyclin D1-regulated Pax6 expression. As shown
in Fig. 5C, overexpression of kinase-dead mutant cyclin D1-K112E
suppressed Pax6 promoter activity. Moreover, treatment of day 3
reprogramming cells with the Cdk4/6 inhibitor PD0332991 also
led to a signiﬁcant reduction of Pax6+ cell clusters and to an
increased proportion of Nanog-expressing cells (Supplementary
Fig. 9A–E), suggesting that both cyclin D1 and CDK4/6 are required
either for NPC maintenance or for suppressing the maintenance of
Nanog+ colonies during cell reprogramming (Fig. 4I and J).
A number of recent studies had revealed that pluripotent stem
cells exhibit a shortened G1 phase [2,10,20]. During the initial
stages of cell differentiation, loss of pluripotency is accompanied
by an increase in the length of the G1 phase [20]. Recent works fur-
ther demonstrated that pluripotent ES cells become more sensitive
to differentiation signals in G1 phase, which is the cause of heter-
ogeneity of pluripotent cells [10]. We therefore speculate that, in
ES and iPS cells, cyclin D1 is only expressed at a very low level or
with a very short half-life in order to ensure the maintenance of
a short G1 phase and undifferentiated status. An increase in the
level of cyclin D1 can either enhance the sensitivity of pluripotent
cells to respond to differentiation stimuli or transcriptionally acti-
vate genes such as Pax6 to promote cell differentiation. We pro-
pose a model to explain how evaluated levels of cyclin D1 during
Yamanaka factor-mediated reprogramming can be linked to neural
progenitor fate commitment (Fig. 5J). During the initial reprogram-
ming, the level of cyclin D1 can be up-regulated by Yamanaka fac-
tors. However, sustained production of cyclin D1 possibly causes
either suppression of pluripotency genes such as Nanog or upregu-
lation of Pax6, which leads reprogramming cells to become NPCs. If
cyclin D1 levels are reduced in reprogramming cells, an ES cell-like
cell cycle structure can be reestablished, which will lead to
complete pluripotency reprogramming.
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